within Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B02B_VitaminKAndOtherHemostatics.B02BD04_CoagulationFactorIx;

model CoagulationFactorIx
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 6.805555555555555e-08,
    adminDuration = 600,
    adminMass = 50 / 1000000,
    adminCount = 1,
    Vd = 0.065,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.033,
    k12 = 4.8611111111111105e-08,
    k21 = 4.8611111111111105e-08);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>CoagulationFactorIx</td></tr><tr><td>ATC code:</td><td>B02BD04</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>50</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>65</td><td>L</td></tr>
    <tr><td>clearance:</td><td>3.5</td><td>ml/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Coagulation factor IX is a plasma glycoprotein essential for the blood coagulation cascade, used in the treatment and prevention of bleeding episodes in patients with hemophilia B (congenital factor IX deficiency). It is an approved medication and available as both plasma-derived and recombinant products.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic model in adult male patients with severe hemophilia B after intravenous administration of recombinant factor IX concentrate.</p><h4>References</h4><ol><li><p>Zhang, Y, et al., &amp; Sidhu, J (2016). Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B. <i>Journal of thrombosis and haemostasis : JTH</i> 14(11) 2132–2140. DOI:<a href=\"https://doi.org/10.1111/jth.13444\">10.1111/jth.13444</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27513989/\">https://pubmed.ncbi.nlm.nih.gov/27513989</a></p></li><li><p>Nazeef, M, &amp; Sheehan, JP (2016). New developments in the management of moderate-to-severe hemophilia B. <i>Journal of blood medicine</i> 7 27–38. DOI:<a href=\"https://doi.org/10.2147/JBM.S81520\">10.2147/JBM.S81520</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27099538/\">https://pubmed.ncbi.nlm.nih.gov/27099538</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.B.B02BD04 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end CoagulationFactorIx;
